NANO Share Price Performance
€23.75
19.33 (437.57%)
Price €23.75
Share Price€23.75
Nanobiotix S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
NANO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Nanobiotix S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -1.07
- 100.00%
- -508.35%
- -69.0%
About NANO
- Founded
- 2003
- Employees
- 103
- CEO
- WebsiteView website
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
